|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.390 USD | +3.65% |
|
+0.56% | +12.53% |
| Dec. 04 | Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study | MT |
| Dec. 04 | FDA Lifts Hold on Vanda Pharmaceuticals' Motion Sickness Drug | DJ |
| Capitalization | 319M 274M 257M 239M 442M 28.67B 480M 3B 1.16B 13.54B 1.2B 1.17B 49.51B | P/E ratio 2025 * |
-2.34x | P/E ratio 2026 * | -3.51x |
|---|---|---|---|---|---|
| Enterprise value | 319M 274M 257M 239M 442M 28.67B 480M 3B 1.16B 13.54B 1.2B 1.17B 49.51B | EV / Sales 2025 * |
1.46x | EV / Sales 2026 * | 1.2x |
| Free-Float |
96.85% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Vanda Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | +3.65% | ||
| 1 week | +0.56% | ||
| Current month | +0.56% | ||
| 1 month | +21.40% | ||
| 3 months | +16.92% | ||
| 6 months | +22.78% | ||
| Current year | +12.53% |
| 1 week | 4.89 |  | 5.79 |
| 1 month | 4.27 | | 5.79 |
| Current year | 3.81 | | 5.79 |
| 1 year | 3.81 | | 5.79 |
| 3 years | 3.3 | | 11.04 |
| 5 years | 3.3 | | 21.86 |
| 10 years | 3.3 | | 33.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2003-04-30 | |
Kevin Moran
DFI | Director of Finance/CFO | 41 | 2020-03-14 |
Scott Howell
HRO | Human Resources Officer | - | 2019-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 2021-05-31 | |
Richard Dugan
BRD | Director/Board Member | 83 | 2005-11-30 |
Phaedra Chrousos
BRD | Director/Board Member | 45 | 2019-04-23 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.34% | 29 M€ | +7.52% | - |
| 0.22% | 22 M€ | +1.27% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.65% | +0.56% | +12.76% | -49.20% | 319M | |
| -2.68% | -1.46% | +30.24% | +105.16% | 54.89B | |
| -0.51% | -1.81% | +170.81% | +925.64% | 43.51B | |
| +0.90% | -0.87% | +75.84% | +15.31% | 38.12B | |
| +0.26% | -6.69% | -19.01% | -42.27% | 23.14B | |
| -1.45% | -0.34% | +30.97% | -37.78% | 19.5B | |
| -0.97% | +4.69% | +98.42% | -40.74% | 17.25B | |
| +0.57% | +0.98% | +89.61% | +302.27% | 14.68B | |
| -2.66% | +2.35% | +4.51% | +2,232.48% | 14.12B | |
| +2.45% | +0.79% | +147.98% | - | 13.78B | |
| Average | -0.04% | -0.30% | +64.21% | +378.99% | 23.93B | |
| Weighted average by Cap. | -0.70% | -1.08% | +72.15% | +355.40% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 218M 188M 176M 164M 302M 19.64B 329M 2.05B 793M 9.27B 819M 801M 33.91B | 265M 228M 214M 199M 368M 23.89B 400M 2.5B 965M 11.28B 996M 975M 41.26B |
| Net income | -136M -117M -110M -102M -189M -12.26B -205M -1.28B -496M -5.79B -511M -500M -21.18B | -92.07M -79.15M -74.14M -69.11M -128M -8.29B -139M -867M -335M -3.91B -346M -338M -14.31B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
368
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 5.390 $ | +3.65% | 1,812,408 |
| 25-12-04 | 5.200 $ | -1.33% | 959,443 |
| 25-12-03 | 5.270 $ | +7.11% | 705,098 |
| 25-12-02 | 4.920 $ | -1.99% | 511,963 |
| 25-12-01 | 5.020 $ | -6.34% | 670,955 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.390USD
Average target price
11.75USD
Spread / Average Target
+118.00%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VNDA Stock
Select your edition
All financial news and data tailored to specific country editions
